Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium

Respiratory Care

Volumn 53, Issue 12, 2008, Pages 1716-1722

  Bonasia, Philip J ^a   McVicar, William K ^b   Williams, Bill ^c   Ong, Shaowei ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b INOTEK CORPORATION   (United States)

^c ABC Laboratories Incorporated   (United States)

Author keywords

Acetylcysteine sodium; Admixture; Asthma; Bronchial asthma; Budesonide; Compatibility; Concentrate; Cromolyn sodium; Ipratropium bromide; Levalbuterol

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; BUDESONIDE; CROMOGLYCATE DISODIUM; IPRATROPIUM BROMIDE; LEVALBUTEROL; ACETYLCYSTEINE; RESPIRATORY TRACT AGENT; SALBUTAMOL;

ARTICLE; CHEMICAL ANALYSIS; DRUG MIXTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; ROOM TEMPERATURE; CHEMISTRY; DRUG COMBINATION; DRUG INCOMPATIBILITY; DRUG STABILITY; INHALATIONAL DRUG ADMINISTRATION; TIME;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; ALBUTEROL; BUDESONIDE; CROMOLYN SODIUM; DRUG INCOMPATIBILITY; DRUG STABILITY; DRUG THERAPY, COMBINATION; IPRATROPIUM; RESPIRATORY SYSTEM AGENTS; TIME FACTORS;

EID: 61449453781     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-S138. Erratum in: J Allergy Clin Immunol 2008;121(6):1330.
2. Roberts GW, Rossi SOP. Compatibility of nebuliser solutions. Aust J Hosp Pharm 1993;23:35-37. (Pubitemid 23091495)
3. Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC Jr, Hudgel DW, et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996;100(1A):62S-69S. (Pubitemid 26060165)
4. Kamin W, Schwabe A, Kramer I. Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5(4):205-213. (Pubitemid 44824857)
5. Pujol MS, Menat C, Henon T, Jacquet M, Woronoff-Lemsi MC. [Prescriptions of aerosol therapy. A survey of practices at the Besançon University Hospital]. Presse Med 2000;29(15):824-828. Article in French.
6. US Food and Drug Administration. Xopenex HFA (levalbuterol tartrate) inhalation aerosol. http://www.fda.gov/cder/foi/label/2005/21730lbl.pdf. Accessed October 8, 2008.
7. Bonasia P, Cook C, Cheng Y, Ong S. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin 2007;23(10):2477-2483. (Pubitemid 350033450)
8. Lee TY, Chen CM, Lee CN, Chiang YC, Chen HY. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health Syst Pharm 2005;62(7):828-833. (Pubitemid 40547367)
9. Joseph JC. Compatibility of nebulizer solution admixtures. Ann Pharmacother 1997;31(4):487-489. (Pubitemid 27155254)
10. Jacobson GA, Peterson GM. High-performance liquid chromatographic assay for the simultaneous determination of ipratropium bromide, fenoterol, salbutamol and terbutaline in nebulizer solution. J Pharm Biomed Anal 1994;12(6):825-832. (Pubitemid 24207472)
11. Lesko LJ, Miller AK. Physical-chemical compatibility of cromolyn sodium nebulizer solution-bronchodilator inhalant solution admixtures. Ann Allergy 1984;53(3):236-238. (Pubitemid 14037141)
12. Emm T, Metcalf JE, Lesko LJ, Chai MF. Update on the physicalchemical compatibility of cromolyn sodium nebulizer solution: bronchodilator inhalant solution admixtures. Ann Allergy 1991;66(2):185-189.
13. Schöni MH, Kraemer R. Osmolality changes in nebulizer solutions. Eur Respir J 1989;2(9):887-892. (Pubitemid 19267632)
14. Gooch MD. Stability of albuterol and tobramycin when mixed for aerosol administration. Respir Care 1991;36(12):1387-1390.
15. Roberts GW, Badcock NR, Jarvinen AO. Cystic fibrosis inhalation therapy: stability of a combined salbutamol/colistin solution. Aust J Hosp Pharm 1992;22:378-380. (Pubitemid 23001720)
16. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004;38(6):967-972. (Pubitemid 38657735)
17. Smaldone GC, McKenzie J, Cruz-Rivera M. Effect of nebulizer volume on drug delivery: budesonide inhalation suspension (abstract). Am J Respir Crit Care Med 2000;161:A36.
18. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998;11:113-125.
19. Clay MM, Newman SP, Pavia D, Lennard-Jones T. Assessment of jet nebulisers for lung aerosol therapy. Lancet 1983;10(8350):592-594.
20. Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med 2006;19(4):484-490. (Pubitemid 46067767)
21. Di Berardino L, Scaglione F. Mixing albuterol and corticosteroid is not additive. Allergy 1999;54(9):1012-1013.
22. Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J, Vadas E. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997;111(5):1206-1212. (Pubitemid 27200073)
23. Kendrick AH, Smith EC, Wilson RS. Selecting and using nebuliser equipment. Thorax 1997;52(Suppl 2):S92-S101.
24. Physicians' Desk Reference. 61st edition. Montvale, NJ: Thompson; 2006.